Panel Discussion: Validating Immunogenicity of Neoantigens & Establishing a Consensus on Selecting Optimal Neoantigen Targets to Generate an Efficacious Immune Response
Time: 12:00 pm
day: Day One
Details:
- Developing a robust, functional validation platform using effector T-cells to validate neoantigen immunogenicity and avoid systemic toxicity
- Establishing a consensus on the most appropriate tools and technologies for ranking and selecting the best neoantigens for targeting
- Characterising neoantigens and selecting an appropriate number for use in therapies to invoke immunogenicity in patients
